Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT05417594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)
Study identification
- NCT ID
- NCT05417594
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 695 participants
Conditions and interventions
Conditions
Interventions
- AZD9574 Drug
- Datopotamab Deruxtecan (Dato-DXd) Drug
- Temozolomide (TMZ) Drug
- Trastuzumab Deruxtecan (T-DXd) Drug
- [11C]AZ1419 3391 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 23, 2022
- Primary completion
- Oct 12, 2027
- Completion
- Oct 12, 2027
- Last update posted
- May 4, 2026
2022 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | La Jolla | California | 92093 | Withdrawn |
| Research Site | Los Angeles | California | 90095 | Recruiting |
| Research Site | San Francisco | California | 94143 | Recruiting |
| Research Site | Chicago | Illinois | 60611 | Recruiting |
| Research Site | Boston | Massachusetts | 02215 | Recruiting |
| Research Site | New York | New York | 10040 | Recruiting |
| Research Site | New York | New York | 10065 | Recruiting |
| Research Site | Portland | Oregon | 97239 | Completed |
| Research Site | Houston | Texas | 77030 | Recruiting |
| Research Site | San Antonio | Texas | 78229 | Not yet recruiting |
| Research Site | Richmond | Virginia | 23298 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05417594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05417594 live on ClinicalTrials.gov.